Trial Profile

A Multicenter Observational Cohort for HIV Infected Patients With a Cancer Treated by Immune-Checkpoint Inhibitors.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Anal cancer; Bladder cancer; Cancer; Head and neck cancer; Hodgkin's disease; Kaposi's sarcoma; Malignant melanoma; Squamous cell cancer; Tongue cancer
Focus Adverse reactions
Acronyms OncoVIHAC

Most Recent Events

02 Apr 2020 New trial record
11 Mar 2020 Results (n=31) assessing immuno-virological parameters in people living with Hiv upon Anti-Pd-1/L-1 for cancer, presented at the 27th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com